New antiplatelet drugs: beyond aspirin and clopidogrel.

Aurangzeb Siddique, Mehmood Butt, Eduard Shantsila, Gregory Lip

Research output: Contribution to journalArticle

20 Citations (Scopus)


Antiplatelet therapy remains a cornerstone of modern management of atherothrombotic vascular disease. For many years, aspirin has been the mainstay of initial antiplatelet drug management in coronary heart disease, while the need for inhibition of other platelet activation pathways has led to the development of various other antiplatelet drugs, such as clopidogrel. An improved understanding of the underlying mechanisms involved in thrombogenesis has paved the way for further development of newer antiplatelet drug therapies. Various clinical studies have probed the effectiveness and risk profile of the newer antiplatelet drugs, such as prasugrel, in comparison with currently available drugs. Some newer agents such as prasugrel are close to being approved for clinical use, whereas other agents such as cangrelor and AZD6140 are in phase 3 clinical trials. New drug classes, such as the thromboxane receptor antagonists (such as NCX-4016 and S18886), as well as platelet adhesion antagonists and thrombin receptor antagonists are similarly being evaluated for their efficacy and risk profile in phase I and II trials.
Original languageEnglish
Pages (from-to)776-89
Number of pages14
JournalInternational Journal of Clinical Practice
Issue number5
Publication statusPublished - 1 May 2009


Dive into the research topics of 'New antiplatelet drugs: beyond aspirin and clopidogrel.'. Together they form a unique fingerprint.

Cite this